Posts Tagged ‘AZD6244’:

Mitogen-activated protein/extracellular signal-regulated kinase

Schad K, Baumann Conzett K, Zipser M “Clinical cancer research 2010″ PURPOSE: Raf/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway is constitutively activated in melanoma. AZD6244 blocks MEK1/2, inhibiting ERK phosphorylation. We focus on associated cutaneous toxicity and we attempt to understand the underlying pathophysiology and design treatment strategies. EXPERIMENTAL DESIGN: Dermatologic conditions of

(Read More…)

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

Dry JR, Pavey S, Pratilas C “Cancer research 2010″ Selumetinib (AZD6244, ARRY-142886) is a selective, non-ATP-competitive inhibitor of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)-1/2. The array of antitumor activity noticed preclinically and in patients highlights the importance of figuring out determinants of response to this drug. In large tumor cell panels of varied lineage, we

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway